Literature DB >> 25645445

Spatial distribution of 5-hydroxymethyl cytosine in rat brain and temporal distribution in striatum.

Tingting Zheng1, Qing Lv, Xiaoguang Lei, Xinzhen Yin, Baorong Zhang.   

Abstract

Recently, 5-hydroxymethyl cytosine (5hmC) was identified in higher organisms as a novel epigenetic modification factor, and was found to be substantially enriched in the central nervous system relative to many other tissues and cell types. Additionally, epigenetic modifications are markedly involved in many neurological disorders. However, the precise role of 5hmC in the brain and neurological diseases remains elusive. To reveal its functional role, a general screen of its spatial and temporal distribution was proposed as being a reasonable starting investigation. Here, we found that 5hmC was widely distributed in the cerebral cortex, striatum, hippocampus, cerebellum, and the brain stem. At the cellular level, 5hmC was widely expressed in neurons and astrocytes even probably the majority of glial cells. Further, the content of 5hmC in different brain regions was inconsistent. Moreover, the pattern of 5hmC in the regions of the whole rat brain was highly susceptible to age-associated modifications. We also found similar phenomena in the striatum, which had not been previously studied. Also, unlike other brain regions, for example in the cerebellum and granulosa cells, 5hmC also appeared to display specific expression in these tissues. However, we didn't obtain the expected result that 5hmC will be increased in 6-hydroxydopamine-induced models of Parkinson's disease with regard the preliminary exploration of 5hmC in these models. Our results suggest that in rats and other mammals, 5hmC likely plays an important role in the brain and is associated with neural development and aging in different areas of the brain.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25645445     DOI: 10.1007/s11064-015-1515-3

Source DB:  PubMed          Journal:  Neurochem Res        ISSN: 0364-3190            Impact factor:   3.996


  33 in total

1.  ATP released by astrocytes mediates glutamatergic activity-dependent heterosynaptic suppression.

Authors:  Jing-ming Zhang; Hui-kun Wang; Chang-quan Ye; Wooping Ge; Yiren Chen; Zheng-lin Jiang; Chien-ping Wu; Mu-ming Poo; Shumin Duan
Journal:  Neuron       Date:  2003-12-04       Impact factor: 17.173

2.  Alpha-synuclein acts in the nucleus to inhibit histone acetylation and promote neurotoxicity.

Authors:  Eirene Kontopoulos; Jeffrey D Parvin; Mel B Feany
Journal:  Hum Mol Genet       Date:  2006-09-07       Impact factor: 6.150

Review 3.  Ageing, neurodegeneration and Parkinson's disease.

Authors:  John V Hindle
Journal:  Age Ageing       Date:  2010-01-05       Impact factor: 10.668

4.  CpG demethylation enhances alpha-synuclein expression and affects the pathogenesis of Parkinson's disease.

Authors:  Lumine Matsumoto; Hiroshi Takuma; Akira Tamaoka; Hiroshi Kurisaki; Hidetoshi Date; Shoji Tsuji; Atsushi Iwata
Journal:  PLoS One       Date:  2010-11-24       Impact factor: 3.240

5.  Striatal histone modifications in models of levodopa-induced dyskinesia.

Authors:  Anthony P Nicholas; Farah D Lubin; Penelope J Hallett; Padmapriya Vattem; Paula Ravenscroft; Erwan Bezard; Shaobo Zhou; Susan H Fox; Jonathan M Brotchie; J David Sweatt; David G Standaert
Journal:  J Neurochem       Date:  2008-07-01       Impact factor: 5.372

6.  Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2).

Authors:  Victoria Valinluck; Hsin-Hao Tsai; Daniel K Rogstad; Artur Burdzy; Adrian Bird; Lawrence C Sowers
Journal:  Nucleic Acids Res       Date:  2004-08-09       Impact factor: 16.971

Review 7.  The 6-hydroxydopamine model of Parkinson's disease.

Authors:  Nicola Simola; Micaela Morelli; Anna R Carta
Journal:  Neurotox Res       Date:  2007-04       Impact factor: 3.911

8.  Increased adenosine A2A receptors in the brain of Parkinson's disease patients with dyskinesias.

Authors:  Frédéric Calon; Mehdi Dridi; Oleh Hornykiewicz; Paul J Bédard; Ali H Rajput; Thérèse Di Paolo
Journal:  Brain       Date:  2004-03-19       Impact factor: 13.501

9.  Genomic and epigenomic insights into nutrition and brain disorders.

Authors:  Margaret Joy Dauncey
Journal:  Nutrients       Date:  2013-03-15       Impact factor: 5.717

10.  Diversity of two forms of DNA methylation in the brain.

Authors:  Yuanyuan Chen; Nur P Damayanti; Joseph Irudayaraj; Kenneth Dunn; Feng C Zhou
Journal:  Front Genet       Date:  2014-03-10       Impact factor: 4.599

View more
  5 in total

1.  Age-dependent levels of 5-methyl-, 5-hydroxymethyl-, and 5-formylcytosine in human and mouse brain tissues.

Authors:  Mirko Wagner; Jessica Steinbacher; Theo F J Kraus; Stylianos Michalakis; Benjamin Hackner; Toni Pfaffeneder; Arshan Perera; Markus Müller; Armin Giese; Hans A Kretzschmar; Thomas Carell
Journal:  Angew Chem Int Ed Engl       Date:  2015-07-03       Impact factor: 15.336

Review 2.  Opening up the DNA methylome of dementia.

Authors:  R Delgado-Morales; M Esteller
Journal:  Mol Psychiatry       Date:  2017-01-03       Impact factor: 15.992

3.  Plasma Exosomes Spread and Cluster Around β-Amyloid Plaques in an Animal Model of Alzheimer's Disease.

Authors:  Tingting Zheng; Jiali Pu; Yanxing Chen; Yanfang Mao; Zhangyu Guo; Hongyu Pan; Ling Zhang; Heng Zhang; Binggui Sun; Baorong Zhang
Journal:  Front Aging Neurosci       Date:  2017-02-01       Impact factor: 5.750

4.  Immunoreactivities of calbindin‑D28k, calretinin and parvalbumin in the somatosensory cortex of rodents during normal aging.

Authors:  Ji Hyeon Ahn; Seongkweon Hong; Joon Ha Park; In Hye Kim; Jeong Hwi Cho; Tae-Kyeong Lee; Jae-Chul Lee; Bai Hui Chen; Bich-Na Shin; Eun Joo Bae; Yong Hwan Jeon; Young-Myeong Kim; Moo-Ho Won; Soo Young Choi
Journal:  Mol Med Rep       Date:  2017-09-21       Impact factor: 2.952

Review 5.  Physiological and pathological implications of 5-hydroxymethylcytosine in diseases.

Authors:  Jing Liang; Fan Yang; Liang Zhao; Chongwei Bi; Benzhi Cai
Journal:  Oncotarget       Date:  2016-07-26
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.